InVivo Therapeutics

$0.5948
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0093 (-1.57%) Today
+$0.0118 (+2.02%) As of 5:39 PM EST after-hours

Why Robinhood?

You can buy or sell NVIV and other stocks, options, and ETFs commission-free!

About NVIV

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA. The listed name for NVIV is InVivo Therapeutics Holdings Corp Common Stock.

CEO
Richard Toselli
Employees
6
Headquarters
Cambridge, Massachusetts
Founded
2005
Market Cap
12.34M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.32M
High Today
$0.6001
Low Today
$0.578
Open Price
$0.5923
Volume
1.47M
52 Week High
$11.99
52 Week Low
$0.4975

Collections

NVIV Earnings

-$0.49
-$0.33
-$0.16
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
Expected Nov 9, After Hours

You May Also Like